CLRB Cellectar Biosciences Inc
Price (delayed)
$0.3021
Market cap
$13.92M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.22
Enterprise value
-$8.87M
Cellectar Biosciences is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company is developing proprietary drugs independently and through research and development collaborations.
Highlights
The company's EPS has surged by 65% YoY and by 29% QoQ
CLRB's quick ratio is up by 47% from the previous quarter
The equity has soared by 194% YoY but it has contracted by 6% from the previous quarter
Cellectar Biosciences's net income has increased by 11% QoQ but it has decreased by 4.2% YoY
Key stats
What are the main financial stats of CLRB
Market
Valuations
Earnings
Shares outstanding
46.08M
Market cap
$13.92M
Enterprise value
-$8.87M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.87
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$51.78M
Net income
-$44.58M
EBIT
-$44.52M
EBITDA
-$44.22M
Free cash flow
-$47.69M
Per share
Balance sheet
Liquidity
EPS
-$1.22
EPS diluted
-$1.4
Free cash flow per share
-$1.3
Book value per share
$0.35
Revenue per share
$0
TBVPS
$0.7
Total assets
$25.47M
Total liabilities
$9.8M
Debt
$494,003
Equity
$14.29M
Working capital
$14.86M
Debt to equity
0.03
Current ratio
2.58
Quick ratio
2.48
Net debt/EBITDA
0.52
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-132%
Return on equity
-328.2%
Return on invested capital
N/A
Return on capital employed
-276.7%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CLRB stock price
How has the Cellectar Biosciences stock price performed over time
Intraday
3.46%
1 week
-16.96%
1 month
4.35%
1 year
-92.43%
YTD
1.04%
QTD
-4.19%
Financial performance
How have Cellectar Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$51.78M
Net income
-$44.58M
Gross margin
N/A
Net margin
N/A
Cellectar Biosciences's operating income has decreased by 33% YoY
Cellectar Biosciences's net income has increased by 11% QoQ but it has decreased by 4.2% YoY
Growth
What is Cellectar Biosciences's growth rate over time
Valuation
What is Cellectar Biosciences stock price valuation
P/E
N/A
P/B
0.87
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS has surged by 65% YoY and by 29% QoQ
The equity has soared by 194% YoY but it has contracted by 6% from the previous quarter
The price to book (P/B) is 86% lower than the last 4 quarters average of 5.9 and 68% lower than the 5-year quarterly average of 2.6
Efficiency
How efficient is Cellectar Biosciences business performance
The company's return on equity has surged by 59% QoQ
The company's return on assets has surged by 58% YoY and by 20% QoQ
Dividends
What is CLRB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CLRB.
Financial health
How did Cellectar Biosciences financials performed over time
The total assets is 160% more than the total liabilities
The total assets has soared by 111% YoY but it has contracted by 32% from the previous quarter
The total liabilities has plunged by 62% YoY and by 53% from the previous quarter
The company's debt is 97% lower than its equity
The equity has soared by 194% YoY but it has contracted by 6% from the previous quarter
The company's debt to equity has surged by 175% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.